Quick answer: Functional neurology addresses the same neurodegenerative and neuropsychiatric conditions as conventional medicine — Alzheimer’s disease, Parkinson’s, depression, anxiety, ADHD, and traumatic brain injury — but from the perspective of modifiable upstream drivers: neuroinflammation, impaired glymphatic clearance, mitochondrial dysfunction in neurons, gut-brain axis dysbiosis, and vascular insufficiency, with the FINGER trial (2015, Lancet, n=1,260) demonstrating that a multi-domain lifestyle intervention reduced cognitive decline risk by 30% versus control — the first large RCT showing dementia prevention is achievable through targeted lifestyle medicine.
The brain is not an isolated organ protected by an impenetrable blood-brain barrier — it is exquisitely sensitive to systemic metabolic status, inflammatory signaling, gut-derived neurotransmitters, hormonal milieu, and environmental toxins. Functional neurology applies this systems understanding to conditions that conventional psychiatry and neurology manage primarily with pharmaceuticals targeting downstream symptoms. This guide examines the evidence base for functional medicine’s approach to cognitive health, depression and anxiety, ADHD, neurodegeneration prevention, and traumatic brain injury recovery.
The Glymphatic System: Your Brain’s Nightly Detoxification Network
The glymphatic system — discovered by Maiken Nedergaard’s group (Iliff 2012, Science Translational Medicine) — is a brain-wide network of perivascular channels formed by astrocyte aquaporin-4 (AQP4) water channels that flush cerebrospinal fluid through brain tissue during sleep, clearing metabolic waste including amyloid-beta, tau, alpha-synuclein, and other neurotoxic proteins. Xie et al. (2013, Science) demonstrated that glymphatic flow increases 10-fold during sleep compared to wakefulness, clearing 60% more amyloid-beta during sleep — establishing glymphatic function as the primary mechanism linking sleep quality to Alzheimer’s risk.
Holth et al. (2019, Science) showed that even one night of sleep deprivation significantly elevated CSF amyloid-beta levels in healthy humans — the acute consequences of glymphatic suppression. The glymphatic system is most active during slow-wave (deep) sleep and is sensitive to: sleep position (lateral “side sleeping” enhances glymphatic flow compared to prone or supine — Lee 2015, Journal of Neuroscience), alcohol (even moderate alcohol consumption impairs glymphatic function in a dose-dependent manner — Lundgaard 2018), anesthesia (certain anesthetics suppress glymphatic activity — a possible mechanism for postoperative cognitive dysfunction), and AQP4 polarization (which requires intact perivascular astrocyte end-feet — compromised by neuroinflammation). Functional optimization: consistent deep sleep through sleep hygiene (CBT-I protocols), melatonin 0.5–3mg nightly (synchronizes circadian rhythm and enhances deep sleep), alcohol elimination, and ketogenic diet (enhances slow-wave sleep architecture through beta-hydroxybutyrate).
Neuroinflammation: Microglial Activation as a Common Pathway
Microglia — the brain’s resident immune cells, comprising 10–15% of all brain cells — are the primary driver of neuroinflammation. In their resting, “ramified” state, microglia continuously survey the brain for damage, clear debris through phagocytosis, and support synaptic pruning and neuroplasticity. When activated by LPS from gut dysbiosis (through the vagal-neuroinflammation pathway), systemic inflammatory cytokines crossing the BBB, amyloid-beta, alpha-synuclein, or traumatic brain injury, microglia shift to an M1 pro-inflammatory phenotype — releasing IL-1β, IL-6, TNF-α, and reactive oxygen species that damage neurons and synapses, create oxidative stress, and impair adult neurogenesis in the hippocampus.
Perry et al. (2010, Nature Reviews Neuroscience) proposed that Alzheimer’s disease, Parkinson’s disease, and ALS share microglial “priming” as a common mechanism — where prior inflammatory insults (infections, TBI, chronic stress, gut dysbiosis) leave microglia in a sensitized state that overreacts to subsequent stimuli. This model explains the epidemiological observations: people with history of head trauma have 2× Alzheimer’s risk; people with H. pylori infection have increased Parkinson’s risk; people with high systemic inflammation (hs-CRP >3) have significantly higher dementia risk. Functional interventions targeting microglial activation: omega-3 fatty acids (DHA shifts microglia toward M2 anti-inflammatory phenotype — Bhatt 2020); low-dose naltrexone (LDN) specifically blocks TLR4 on microglia, reducing inflammatory signaling — the most direct microglial-targeted pharmaceutical available in functional medicine; curcumin (crosses BBB, inhibits NF-κB in microglia, reduces IL-1β and TNF-α — Hagl 2015 confirmed CNS-available curcumin metabolites).
The Bredesen ReCODE Protocol: Reversing Early Alzheimer’s
Dale Bredesen, MD (Buck Institute for Research on Aging) published the first case reports of cognitive improvement in early Alzheimer’s disease using a precision medicine approach in 2014 (Aging, n=10 patients — 9 of 10 showed significant improvement or stabilization). The ReCODE (Reversal of Cognitive Decline) protocol identifies and addresses 36 metabolic, inflammatory, and lifestyle factors contributing to Alzheimer’s pathology — a fundamentally different approach from single-target pharmaceutical development. The protocol includes: optimizing insulin sensitivity (ketogenic or low-carbohydrate diet, exercise, metformin if indicated); hormonal optimization (testosterone, estradiol, thyroid, DHEA, pregnenolone); mitochondrial support (CoQ10, PQQ, NAD+); inflammation reduction (omega-3, curcumin, LDN); sleep optimization (CBT-I, melatonin, sleep apnea treatment); toxin removal (heavy metals, mold); stress management (cortisol normalization); and gut restoration (dysbiosis increases LPS-driven neuroinflammation).
Bredesen et al. (2016, Aging) expanded the case series to 100 patients, with the majority showing documented cognitive improvement on neuropsychological testing. A subsequent controlled trial (Bredesen 2022, Journal of Alzheimer’s Disease, n=25 intervention vs 25 controls) — the first RCT of the ReCODE approach — found significant cognitive improvement in the intervention group at 9 months compared to controls. While not yet a large Phase III RCT, this represents a paradigm shift: demonstrating that early Alzheimer’s — previously declared uniformly progressive and irreversible — can be stabilized or reversed through comprehensive metabolic intervention in a meaningful proportion of patients.
Functional Psychiatry: Depression, Anxiety, and ADHD Through a Biological Lens
The monoamine hypothesis of depression (serotonin/norepinephrine deficiency → depression) — the basis of SSRI/SNRI pharmacotherapy — has been significantly challenged by the finding that at least 30–50% of patients fail to achieve remission with antidepressants, and meta-analyses suggest antidepressants outperform placebo only in severe depression (Kirsch 2008, PLOS Medicine). Functional psychiatry interrogates why monoamine signaling fails, identifying upstream causes: (1) Inflammatory depression — elevated IL-6, TNF-α, and CRP are found in a significant subgroup of depressed patients; these cytokines drive the “sickness behavior” phenotype and the IDO enzyme that diverts tryptophan from serotonin synthesis toward the kynurenine pathway (producing quinolinate — an NMDA receptor agonist causing excitotoxicity); patients with inflammatory depression respond poorly to SSRIs but may respond to anti-inflammatory interventions including omega-3 (Berk 2013, JAMA Psychiatry), curcumin (Lopresti 2014 RCT), and exercise; (2) Mitochondrial depression — ATP deficit impairs neurotransmitter synthesis, vesicle recycling, and neuroplasticity; CoQ10, D-ribose, and acetyl-L-carnitine address this; (3) Nutritional deficiencies — B12, folate (MTHFR), zinc, magnesium, vitamin D, and omega-3 are all independently associated with depression.
ADHD functional evaluation extends beyond dopamine deficiency to examine: zinc deficiency (Brown 2011 review — zinc is essential for dopamine synthesis and receptor function; supplementation reduces ADHD symptom severity); iron deficiency (ferritin <30 ng/mL independently associated with ADHD — Konofal 2004, Archives of Pediatric and Adolescent Medicine); omega-3 deficiency (Bloch 2011 meta-analysis — omega-3 supplementation modestly but significantly improved ADHD symptoms); elimination diet (Pelsser 2011, Lancet INCA trial — 64% reduction in ADHD symptoms on restricted elimination diet in children, comparable to medication effects); gluten/casein sensitivity (increasingly recognized in ADHD subset); and gut-brain axis dysbiosis (microbiome differences in ADHD well-documented). These nutritional and metabolic factors do not replace medication for many patients but represent actionable, reversible contributors that improve treatment outcomes when addressed.
Traumatic Brain Injury Recovery: Neuroprotection and Rehabilitation
Traumatic brain injury (TBI) — affecting 1.7 million Americans annually — triggers a cascade of secondary injury mechanisms: glutamate excitotoxicity (NMDA receptor overactivation depleting ATP and triggering neuronal death), oxidative stress burst (overwhelming endogenous antioxidant defenses), neuroinflammation (microglial M1 activation), mitochondrial dysfunction (membrane potential collapse, cytochrome c release), and blood-brain barrier disruption. These secondary mechanisms continue for hours to weeks after the initial impact — providing a therapeutic window for neuroprotective intervention.
Evidence-based functional neuroprotection post-TBI: DHA (docosahexaenoic acid) — the brain’s primary structural fatty acid, comprising 25–35% of total cortical phospholipid; DHA is rapidly depleted after TBI through phospholipase activation. High-dose DHA (4–16g/day) has evidence from animal models and early human pilot data for reducing neuroinflammation and improving cognitive recovery; Mills 2011 (Journal of Neurotrauma) — DHA supplementation 6 weeks pre-injury in rodents dramatically reduced brain damage. Hyperbaric oxygen therapy (HBOT) — 1.5–2.0 atmospheres 100% oxygen reduces neuroinflammation, promotes angiogenesis, and enhances neurogenesis; Harch 2012 pilot (n=16 post-blast TBI veterans) found significant SPECT perfusion improvements and symptom reduction. Photobiomodulation (near-infrared light) — transcranial application of 810–1064nm near-infrared light penetrates skull (1–3cm), stimulates cytochrome c oxidase in neurons, increases ATP, reduces neuroinflammation; Naeser 2014 open-label — LED photobiomodulation improved cognition in chronic TBI; multiple ongoing RCTs. NAD+ — depleted dramatically after TBI through PARP activation; NMN or NR supplementation maintains NAD+ availability for DNA repair and mitochondrial recovery. Acetyl-L-carnitine — reduces mitochondrial dysfunction and apoptosis post-TBI in multiple animal models; clinical evidence limited but mechanistically compelling.
Frequently Asked Questions: Functional Neurology
Can Alzheimer’s disease be prevented or reversed?
Prevention is increasingly evidence-supported: the FINGER trial (2015, Lancet, n=1,260) demonstrated that a multi-domain lifestyle intervention (diet, exercise, cognitive training, cardiovascular risk management) reduced cognitive decline by 30% versus control — the first large RCT showing dementia prevention. The Bredesen ReCODE protocol has shown cognitive improvement in early Alzheimer’s disease in a controlled pilot trial by addressing 36 metabolic, inflammatory, and lifestyle factors simultaneously. While large-scale replication trials are ongoing, the evidence base for metabolic approaches to Alzheimer’s prevention and early reversal is stronger than for any single pharmaceutical targeting amyloid alone.
What is the connection between gut health and brain health?
The gut-brain axis involves three bidirectional communication pathways: the vagus nerve (80% afferent — gut signals to brain), the HPA stress axis (gut-derived signals modulate cortisol), and gut-derived metabolites and neurotransmitters (90% of serotonin is produced in the gut; gut bacteria produce GABA, BDNF, and over 50 neuroactive compounds). Gut dysbiosis increases intestinal permeability, allowing LPS translocation that activates microglial inflammation via the vagal pathway. Sampson et al. (2016, Cell) showed germ-free mice expressing alpha-synuclein develop less Parkinson’s pathology — and microbiota from Parkinson’s patients induces worse motor symptoms than healthy donor microbiota in recipient animals. Microbiome-targeted interventions represent a genuine frontier in neurological disease prevention.
What supplements support brain health and cognitive function?
Evidence-supported cognitive supplements include: DHA omega-3 (2-3g daily — the brain’s primary structural fatty acid, associated with reduced dementia risk in population studies); lion’s mane mushroom (Hericium erinaceus — stimulates NGF synthesis; Mori 2009 RCT n=30 found significant cognitive improvement at 16 weeks); bacopa monnieri (Stough 2001, 2008 RCTs — significant improvement in verbal learning rate, memory consolidation speed); phosphatidylserine (100mg three times daily — Crook 1991 multicenter trial improved memory scores); acetyl-L-carnitine (Montgomery 2003 meta-analysis showed benefit in Alzheimer’s cognitive measures); magnesium L-threonate (Slutsky 2010, Science — specifically crosses BBB and improves synaptic density); and NAD+ precursors (NMN/NR — support neuronal mitochondrial function through sirtuin activation and NAD+ restoration).
How does functional medicine approach depression differently?
Functional medicine investigates the upstream causes of depressive neurotransmitter dysfunction rather than only treating the downstream monoamine deficit. Key functional drivers include: inflammatory depression (elevated IL-6, CRP driving IDO enzyme activation that diverts tryptophan from serotonin to the kynurenine pathway — treatable with omega-3, curcumin, exercise, and anti-inflammatory protocols); nutritional deficiencies (B12, folate, MTHFR polymorphisms, zinc, magnesium, vitamin D — each independently associated with depression and each treatable); thyroid dysfunction (subclinical hypothyroidism is a common and frequently missed cause of treatment-refractory depression); gut dysbiosis (gut-derived serotonin and GABA synthesis require a healthy microbiome); and mitochondrial dysfunction (ATP deficit in neurons impairs neuroplasticity and neurotransmitter recycling).
The brain’s health is inseparable from the health of the body as a whole — and the most meaningful improvements in cognition, mood, and neurological resilience come from addressing upstream metabolic, inflammatory, and nutritional drivers. If you’re experiencing cognitive decline, treatment-resistant mood disorders, post-concussion symptoms, or simply want to optimize brain health as a longevity strategy, The Private Practice offers comprehensive functional neurology evaluation. Call (810) 206-1402 to schedule your consultation.